for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Stryker Corporation

SYK.N

Latest Trade

206.25USD

Change

3.09(+1.52%)

Volume

491,093

Today's Range

203.60

 - 

206.46

52 Week Range

144.77

 - 

223.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Stryker Reports Third Quarter Adjusted Earnings Per Share Of $1.91

Oct 29 (Reuters) - Stryker Corp <SYK.N>::STRYKER REPORTS THIRD QUARTER 2019 OPERATING RESULTS.SEES Q4 ADJUSTED EARNINGS PER SHARE $2.43 TO $2.48.Q3 ADJUSTED EARNINGS PER SHARE $1.91.Q3 EARNINGS PER SHARE $1.23.Q3 SALES $3.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.58 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.90 -- REFINITIV IBES DATA.EXPECT 2019 ORGANIC NET SALES GROWTH TO BE TOWARD HIGHER END OF OUR PREVIOUSLY GUIDED RANGE OF 7.5% TO 8.0%.NOW EXPECT 2019 ORGANIC NET SALES GROWTH TO BE TOWARD HIGHER END OF OUR PREVIOUSLY GUIDED RANGE OF 7.5% TO 8.0%.EXPECT 2019 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $8.20 TO $8.25.Q3 ORGANIC NET SALES INCREASED 8.6%.IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, CO EXPECT Q4 NET SALES AND FY WILL BE NEGATIVELY IMPACTED BY ABOUT 1.0%.STRYKER-IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, CO SEES NET EARNINGS PER DILUTED EARNINGS PER SHARE NEGATIVELY IMPACTED ABOUT $0.02 IN Q4 & $0.15 FY.

Conformis And Stryker Execute Development, License And Distribution Agreements

Oct 1 (Reuters) - Conformis Inc <CFMS.O>::CONFORMIS AND STRYKER EXECUTE DEVELOPMENT, LICENSE AND DISTRIBUTION AGREEMENTS.CONFORMIS INC - CONFORMIS WILL RECEIVE $14M UP-FRONT AND UP TO AN ADDITIONAL $16M IN MILESTONE PAYMENTS.CONFORMIS - ENTERED INTO A LONG-TERM DISTRIBUTION AGREEMENT WITH STRYKER, UNDER WHICH CO TO SUPPLY PSI TO STRYKER.

Stryker Announces Definitive Agreement To Acquire Mobius Imaging & Cardan Robotics

Sept 4 (Reuters) - Stryker Corp <SYK.N>::STRYKER ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE MOBIUS IMAGING & CARDAN ROBOTICS.STRYKER CORP - DEAL FOR ALL CASH OF ABOUT $370 MILLION UPFRONT AND UP TO $130 MILLION OF CONTINGENT PAYMENTS.STRYKER CORP - TRANSACTION IS EXPECTED TO HAVE AN IMMATERIAL IMPACT TO NET EARNINGS IN 2019.

Stryker Corp Declares A $0.52 Per Share Quarterly Dividend

July 31 (Reuters) - Stryker Corp <SYK.N>::STRYKER DECLARES A $0.52 PER SHARE QUARTERLY DIVIDEND.

Stryker Q2 Adjusted Earnings Per Share $1.98

July 25 (Reuters) - Stryker Corp <SYK.N>::STRYKER REPORTS SECOND QUARTER 2019 OPERATING RESULTS.SEES Q3 ADJUSTED EARNINGS PER SHARE $1.87 TO $1.92.Q2 ADJUSTED EARNINGS PER SHARE $1.98.Q2 EARNINGS PER SHARE $1.26.Q2 SALES $3.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.6 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.94 -- REFINITIV IBES DATA.QTRLY ORGANIC NET SALES INCREASED 8.5%.NOW EXPECT 2019 ORGANIC NET SALES GROWTH TO BE IN RANGE OF 7.5% TO 8.0%.EXPECT 2019 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $8.15 TO $8.25.FOR Q3 EXPECT ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $1.87 TO $1.92.IF FOREX RATES HOLD NEAR CURRENT LEVELS, EXPECT NET SALES IN Q3 WILL BE NOMINALLY IMPACTED AND FULL YEAR WILL BE NEGATIVELY IMPACTED.STRYKER - IF FOREX RATES HOLD NEAR CURRENT LEVELS, Q3 NET EARNINGS/SHARE WILL BE NOMINALLY IMPACTED & NEGATIVELY IMPACTED BY ABOUT $0.10 IN FULL YEAR.FY2019 EARNINGS PER SHARE VIEW $8.15, REVENUE VIEW $14.79 BILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $1.90, REVENUE VIEW $3.57 BILLION -- REFINITIV IBES DATA.

Stryker Receives FDA Premarket Approval For The Neuroform Atlas Stent System To Treat Brain Aneurysms

May 20 (Reuters) - Stryker Corp <SYK.N>::STRYKER RECEIVES FDA PREMARKET APPROVAL FOR THE NEUROFORM ATLAS STENT SYSTEM TO TREAT BRAIN ANEURYSMS.

Stryker Declares A $0.52 Per Share Quarterly Dividend

May 1 (Reuters) - Stryker Corp <SYK.N>::STRYKER DECLARES A $0.52 PER SHARE QUARTERLY DIVIDEND.

FDA Reminds Health Care Professionals About Risks Of Wingspan Stent System

April 25 (Reuters) - U.S. Food and Drug Administration::FDA REMINDS HEALTH CARE PROFESSIONALS ABOUT RISKS OF WINGSPAN STENT SYSTEM AFTER STUDY SHOWS INCREASED RISK OF STROKE OR DEATH WHEN USED OUTSIDE OF THE FDA-APPROVED INDICATIONS.FDA - STUDY SHOWING INCREASED RISK OF STROKE IN WINGSPAN STENT SYSTEM CONDUCTED IN FOLLOW UP TO FDA ACTIONS IN 2012 TO ADDRESS SAFETY CONCERNS WITH DEVICE.

Stryker Q1 Adjusted Earnings Per Share $1.88

April 23 (Reuters) - Stryker Corp <SYK.N>::STRYKER REPORTS FIRST QUARTER 2019 OPERATING RESULTS.SEES Q2 ADJUSTED EARNINGS PER SHARE $1.90 TO $1.95.Q1 ADJUSTED EARNINGS PER SHARE $1.88.Q1 EARNINGS PER SHARE $1.09.Q1 SALES $3.5 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.52 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.84 -- REFINITIV IBES DATA.NOW EXPECT 2019 ORGANIC NET SALES GROWTH TO BE IN RANGE OF 6.8% TO 7.5%.QTRLY ORGANIC NET SALES INCREASED 7.3%.Q2 EARNINGS PER SHARE VIEW $1.96 -- REFINITIV IBES DATA.STRYKER - EXPECT 2019 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $8.05 TO $8.20.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, WE EXPECT NET SALES IN Q2 WILL BE NEGATIVELY IMPACTED BY APPROXIMATELY 1.5%.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, EXPECT NET SALES IN FULL YEAR WILL BE NEGATIVELY IMPACTED BY APPROXIMATELY 1.0%.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, EXPECT NET EPS WILL BE NEGATIVELY IMPACTED BY $0.01 TO $0.03 IN Q2.STRYKER - IF FOREIGN CURRENCY EXCHANGE RATES HOLD NEAR CURRENT LEVELS, EXPECT NET EPS WILL BE NEGATIVELY IMPACTED BY $0.05 TO $0.10 IN FULL YEAR..FY2019 EARNINGS PER SHARE VIEW $8.13 -- REFINITIV IBES DATA.

Stryker Acquires Orthospace Ltd

March 14 (Reuters) - Stryker Corp <SYK.N>::STRYKER ACQUIRES ORTHOSPACE, LTD..STRYKER CORP - ALL CASH TRANSACTION FOR AN UPFRONT PAYMENT OF $110 MILLION AND FUTURE MILESTONE PAYMENTS OF UP TO AN ADDITIONAL $110 MILLION..STRYKER CORP - TRANSACTION IS EXPECTED TO HAVE AN IMMATERIAL IMPACT TO NET EARNINGS IN 2019..STRYKER CORP - DEAL FOR AN UPFRONT PAYMENT OF $110 MILLION AND FUTURE MILESTONE PAYMENTS OF UP TO AN ADDITIONAL $110 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up